Samik Pharm KRX:014950KOSDAQ
삼익제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days3
DART filings, 7 days0
Articles tracked22since Sep 11
In Q2 2026, Samik Pharm reported revenue of ₩15.7bn, up 5.2% year on year, and an operating loss of ₩228m. Samik Pharm (삼익제약) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 4 articles. It was most often mentioned alongside Hwail Pharm, ChoA Pharmaceutical and Hyundai Pharmaceutical.
Filing signals Swung to loss Screener
Samik Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩15.7bn | +5.2% | −₩228m margin −1.4% | −₩77m |
| Q1 2026 | ₩15.5bn | +10.4% | ₩929m margin 6.0% | ₩1.2bn |
| Q4 2025 derived | ₩15.2bn | +8.1% | ₩49m margin 0.3% | −₩3.6bn |
| Q3 2025 | ₩15.8bn | +11.2% | ₩1.1bn margin 6.8% | ₩937m |
| Q2 2025 | ₩14.9bn | +4.9% | ₩1.1bn margin 7.6% | ₩716m |
| Q1 2025 | ₩14.0bn | – | ₩1.0bn margin 7.2% | ₩1.2bn |
| Q4 2024 derived | ₩14.1bn | – | ₩501m margin 3.6% | ₩426m |
| Q3 2024 | ₩14.2bn | – | ₩1.3bn margin 9.2% | ₩1.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Samik Pharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Samik Pharm news Korean headlines
-
인피니트헬스케어 654억 배당에 上…삼익제약 주목[바이오맥짚기]
1 more on this story · 1 outlets
- 인피니트헬스케어 654억 배당에 上…삼익제약 주목[바이오맥짚기]이데일리 · Sep 16 08:31
-
KRX 애프터마켓 첫 시행… 광전자·빛과전자·삼익제약 거래량 급증
1 more on this story · 1 outlets
- KRX 애프터마켓 첫날…광전자·빛과전자 등 거래량 상위권아주경제 · Sep 14 17:02